Why Non-Human Primates (NHPs) for AAV/Lentiviral Gene Therapies

Are you currently facing unpredictable vector toxicity and translational failure in your AAV or lentiviral programs? Creative Biolabs is proud to Drive Innovation. Define the Future of Gene Therapy. We help you de-risk your development path and accelerate IND submission through advanced NHP in vivo screening and multi-modality vector assessment, ensuring human-relevant safety and efficacy data.

NHP Models: Translational Certainty for Clinical Success.

NHP models provide essential, human-relevant in vivo data on vector biodistribution, long-term persistence, and late-onset immunogenicity, directly supporting successful regulatory submissions.

Get a Quote

Overview of NHP Applications

Our NHP based services are designed not just to test safety, but to generate the human-relevant data that validates next-generation, engineered vectors (like those developed via Directed Evolution) and novel vector systems (such as Non-Primate Lentiviruses, which offer inherent safety advantages).

What Are Our Research Areas?

The successful translation of AAV and Lentiviral gene therapies relies entirely on validating vector performance in a preclinical system that accurately mirrors human physiology. This critical phase, the final hurdle before clinical trials, requires generating longitudinal data on the vector's long-term behavior in a relevant host.

Why Choose Us?

The reliance on rodent models often leads to translational failures because they fail to replicate the scale, metabolism, and immune complexity of humans. Creative Biolabs leverages NHP models because they offer:

• Genetic and Immunological Homology: NHPs share significant genetic similarity and a highly relevant immune system structure and function with humans, providing the most accurate prediction of human immune responses.
• Clinical Translational Relevance: NHP data on vector biodistribution, target organ specificity (like the critical vascular endothelium identified in cutting-edge research), and target engagement profiles are often required for Gene Therapy Investigational New Drug (IND) submissions.
• Data Types Required for Regulatory Submissions: NHPs enable the collection of clinically analogous data (PK/PD, toxicology endpoints, vector shedding profiles) using the same analytical techniques (e.g., ddPCR, ELISA) intended for clinical trials, ensuring data fidelity from preclinical to clinical phases.

Fig.1 Assessment and biodistribution of individual AAV mutants in marmosets.¹

Key Applications

NHPs provide specific, non-replicable data points essential for regulatory approval and clinical success by allowing researchers to address human-specific challenges:

• Vector Biodistribution and Shedding Studies for AAV Therapies: Precisely mapping the vector genome copy number across dozens of tissues (including liver, gonads, and CNS) following systemic or localized delivery. This data is critical to demonstrate target specificity, assess off-target risks, and establish required clinical dose ranges, particularly for engineered capsids designed for superior tissue penetration.
• Immunogenicity and Neutralizing Antibody (NAb) Assessment: Quantifying the formation of ADAs and NAbs against the AAV or Lentiviral capsid over time, directly correlating the immune response with efficacy decline. This guides crucial patient selection, exclusion criteria, and pre-dosing strategies in clinical protocols.
• Targeted Vector Efficacy in Complex Tissues (CNS/Ocular): Assessing the efficacy and persistence of engineered vectors (AAV or Non-Primate Lentivirus) in anatomically complex, non-dividing cell populations, such as photoreceptors in the eye or specific neuron populations in the brain, validating the utility of next-generation targeted capsids.

How Do Creative Biolabs Support Your Projects?

Creative Biolabs offers a seamless, integrated suite of services tailored specifically for advanced gene therapy modalities. Our end-to-end support ensures that every phase of your NHP study generates high-quality, regulatory-compliant data.

Translational Impact

Choosing Creative Biolabs' NHP-driven approach is the most efficient method to de-risk your gene therapy program, ensuring your vector's safety and efficacy are robustly validated in a system highly predictive of the human response.

• More Reliable Early Proof of Concept: By utilizing NHP models, we generate data that is far more predictive than rodent data, which is essential when translating engineered vector targets.
• Early Detection of Immune Responses/Toxicity: Our rigorous immunogenicity and safety pharmacology assays enable the early detection of potentially dose-limiting toxicities and immune responses, which helps reduce the risk of clinical hold or IND failure.
• Reduced Risk of IND Failure: NHP biodistribution data is often explicitly required for gene therapy IND submissions. Creative Biolabs ensures you have the necessary documentation and data integrity to support a successful regulatory application the first time.

Frequently Asked Questions

Contact Us

Creative Biolabs is dedicated to providing the necessary human-relevant data to advance your gene therapy program. By integrating NHP-based in vivo screening, GLP safety studies, and state-of-the-art bioanalytical services, we minimize the translational risk inherent in complex vector modalities. To discuss a customized NHP study design, receive a detailed quote, Contact Our Team for More Information and Discuss Your Project.